**BETA3-ADRENERGIC RECEPTOR BLOCKADE BY APD418 ENHANCES CARDIAC POSITIVE INOTROPIC AND LOSITROPIC RESPONSES TO DOBUTAMINE IN HEART FAILURE: ASSESSMENT BY PRESSURE-VOLUME ANALYSIS**

X. Zhang1, Z. Zhang2, T. Li3, H.-J. Cheng4, D. Deal5, J. Jordan6, J. Adams7, **C. Cheng**8

1Cardiology, Wake Forest School of Medicine, Winston-Salem, NC, USA

2Cardiology, Wake Forest School of Medicine, Winston-Salem, NC, USA

3Section on Cardiovascular Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

4Cardiology, Wake Forest School of Medicine, Winston-Salem, NC, USA

5SurgSci Cardiothoracic Surgery, Wake Forest School of Medicine, Winston-Salem, NC, USA

6Surgery Cardiothoracic, Wake Forest School of Medicine, Winston-Salem, NC, USA

7Arena Pharmaceuticals, Inc, San Diego, CA, USA

8Wake Forest School of Medicine, Winston-Salem, NC, USA

**Objective.**To assess the hypothesis that APD418, a novel, potent, selective, human β3-AR antagonist (β3-ANT), may restore cardiac positive responses to dobutamine (DOB) in heart failure (HF).

**Background.** Attenuation of HF response to positive inotropic agents such as DOB represents a major clinical problem. The regulation of cardiac function by catecholamine involves 3 populations of β-adrenergic receptors (AR). β1-and β2-AR stimulation produces an increase in contractility, and β3-AR stimulation mediates a negative inotropic effect. In HF, β3-AR-mediated negative action is increased due to β3-AR upregulation. Since DOB is a non-selective β-AR agonist, the diminished response of DOB in HF patients may be caused by DOB-induced β3-AR stimulation.

**Methods.** We compared the effect of APD418 (1.9 mg/kg, i.v., 10 min) on left ventricular (LV) contractile response to DOB (6 μg/kg/min, iv, 10 min) in 5 chronically-instrumented, conscious dogs after pacing-induced HF. LV contractility was measured by pressure (P)-volume (V) analysis.

**Results.** After HF, DOB caused a 25% increase in LV contractility (EES) (5.3±1.7 vs 4.2±1.3 mmHg/ml), a 13% increase in MSW (58.7±3.8 vs 51.1±2.9 mmHg), and a 9% decrease in the time constant of LV relaxation (τ) (41.0±2.9 vs 45.2±4.1 ms). APD418 infusion resulted in APD418 plasma levels of ~2800 ng/ml. DOB followed by APD418 resulted in significantly greater effects with a 73% increase in EES (7.2±2.7 vs 4.2±1.3 mmHg/ml), a 47% increase in MSW (75.0±4.8 vs 51.1±2.9 mmHg), and a 21% decrease in τ (35.9±3.4 vs 45.2±4.1 ms). Compared with DOB alone, DOB plus APD418 caused no significant changes in heart rate (128 vs 124 bpm) or LV end-systolic P (107 vs 105 mmHg), but significantly increased stroke volume (15.0±2.2 vs 11.4±1.9 ml). DOB plus APD418 significantly improved LV mechanical efficiency, measured as the ratio of stroke work to the total P-V area (0.61±0.18 vs 0.47±0.17).

**Conclusion.** In pacing-induced HF, APD418 enhanced LV positive inotropic and lusitropic responses to dobutamine. This suggests combination therapy with intravenous β3-ANT and DOB may be appropriate in HF, providing a potential method of enhancing β-adrenergic responsiveness in the failing myocardium.